Morpholino

MO3-sulf2a

ID

ZDB-MRPHLNO-210215-1

Name

MO3-sulf2a

Previous Names

sulf2aMOsplice (1)

Target

sulf2a (1)

Sequence

5' - GAAACTATACTGTGACCCACTCTTC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO3-sulf2a

Expressed Gene	Anatomy	Figures
olig2	spinal cord motor neuron	Figure 4 , Figure 5 from Danesin et al., 2021
sim1a	spinal cord interneuron	Figure 2 from Danesin et al., 2021

Phenotype

Phenotype resulting from MO3-sulf2a

Phenotype	Fish	Figures
oligodendrocyte cell fate specification decreased occurrence, abnormal	vu19Tg + MO3-sulf2a	Figure 3 , Figure 4 , Figure 6 from Danesin et al., 2021
spinal cord olig2 expression decreased amount, abnormal	vu17Tg + MO3-sulf2a	Figure 5 from Danesin et al., 2021
spinal cord motor neuron olig2 expression decreased amount, abnormal	vu17Tg + MO3-sulf2a	Figure 4 from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal	vu17Tg; vu19Tg + MO3-sulf2a	Figure 3 , Figure 4 , Figure 6 from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal	vu17Tg + MO3-sulf2a	Figure 2 , Figure 4 from Danesin et al., 2021
spinal cord interneuron sim1a expression increased amount, abnormal	WT + MO3-sulf2a	Figure 2 from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal	vu17Tg + MO3-sulf2a	Figure 2 , Figure 4 from Danesin et al., 2021

Phenotype of all Fish created by or utilizing MO3-sulf2a

Phenotype	Fish	Conditions	Figures
spinal cord interneuron sim1a expression increased amount, abnormal	WT + MO3-sulf2a	standard conditions	Figure 2 from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal	WT + MO3-sulf2a	standard conditions	Figure 2 from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal	WT + MO3-sulf2a	standard conditions	Figure 2 from Danesin et al., 2021
spinal cord olig2 expression decreased amount, abnormal	vu17Tg + MO3-sulf2a	control	Figure 5 from Danesin et al., 2021
spinal cord motor neuron olig2 expression decreased amount, abnormal	vu17Tg + MO3-sulf2a	control	Figure 4 from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal	vu17Tg + MO3-sulf2a	control	Figure 4 from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal	vu17Tg + MO3-sulf2a	control	Figure 4 from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal	vu17Tg + MO3-sulf2a	control	Figure 4 from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal	vu17Tg + MO3-sulf2a	control	Figure 4 from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal	vu19Tg + MO3-sulf2a	standard conditions	Figure 3 from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal	vu19Tg + MO3-sulf2a	standard conditions	Figure 3 from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal	vu17Tg; vu19Tg + MO3-sulf2a	standard conditions	Figure 6 from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal	vu17Tg; vu19Tg + MO3-sulf2a	standard conditions	Figure 6 from Danesin et al., 2021

Citations